|
|
Article: Schering-plough vies to quash generic OTC claritin. (Life Sciences).(Has filed separate suits against divisions of Johnson & Johnson and American Home Products Corp.)(Brief Article)
- Article from:
- Chemical Market Reporter
- Article date:
- February 11, 2002
- Author:
CopyrightCOPYRIGHT 2002 Schnell Publishing Company, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
IN A MOVE to block generic over-the-counter (OTC) competition for its $3.2 billion antihistamine Claritin (loratadine) and lock-in sales of Clarinex (desloratadine), a newly launched successor, Schering-Plough Corp. (SHP) has filed separate suits against divisions of Johnson & Johnson (J&J) and American Home Products Corp. (AHP).
If victorious in an upcoming trial against generic firms seeking to market prescription loratadine, SHP will potentially impede generic prescription and OTC Claritin until October 2004. ABN Amro and Prudential Financial estimate patent expiration for Claritin in December 2002.
SHP charges the applications for OTC generic ...